To report outcomes after yttrium-90 microsphere brachytherapy for unresectable liver metastases from uveal melanoma and to evaluate factors predictive for overall survival (OS) and hepatic progression-free survival (PFS).
U veal melanoma is the most common primary intraocular malignant tumor among adults and represents 3% of all melanoma cases. 1 Despite treatment of the primary tumor, half of the patients will develop systemic metastasis. 2 Interestingly, the liver is the first site of metastatic disease in 75% to 90% of patients and, ultimately, half of these patients will never develop metastatic disease beyond the liver. 3, 4 Without aggressive treatment, survival after the discovery of liver metastases ranges only 3 to 12 months and, unfortunately, mortality rates have not changed significantly over the past 3 decades. 1, [4] [5] [6] [7] [8] [9] Given that the liver is the predominant organ of involvement in most patients, liver-directed therapies are paramount in the management of metastatic uveal melanoma. In fact, the reported response rates and survival times after local, liver-directed therapies are superior to those following systemic chemotherapy, which seems to have limited efficacy. 4, 6, [10] [11] [12] Thus, first-line therapies for liver metastases from uveal melanoma generally include: surgical resection, transarterial chemoembolization (TACE), immunoembolization, and isolated hepatic perfusion. [10] [11] [12] [13] [14] [15] [16] In many patients, surgical resection of liver metastases is not feasible due to the multiplicity of lesions or multisegmental involvement so, catheterdirected liver therapies are frequently used. Despite these treatment options, most patients will develop progression of their liver metastases after their first intervention.
Liver brachytherapy with yttrium-90 ( 90 Y) microspheres, also known as selective internal radiotherapy or radioembolization, has emerged as a valuable therapeutic option for patients with liver tumors. Recently, 90 Y microsphere brachytherapy has been demonstrated to be a safe and effective salvage therapy for patients with metastatic uveal melanoma who progress after standard therapies. 17, 18 Few institutions have reported their experience with microsphere brachytherapy for treatment of liver metastases from uveal melanoma. Reported local control and median survival times after treatment range from 62% to 77% and 7 to 10 months, respectively. [17] [18] [19] [20] [21] Compared with purely morphologic imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI), fluorodeoxyglucose positron emission tomography (FDG PET) provides the distinctive ability to characterize tumor metabolism with anatomic correlation from a coregistered CT scan (PET/CT). Recently, data have emerged to propose that PET-derived functional tumor parameters predict survival after 90 Y liver brachytherapy in patients with metastases from colorectal cancer, breast cancer, cholangiocarcinoma, and melanoma from mixed cutaneous and ocular origin. [21] [22] [23] [24] However, the predictive value of functional tumor parameters like maximum standard uptake value (SUV max ), metabolic tumor volume (MTV), and total glycolic activity (TGA) in patients with liver metastases from primary uveal melanoma is not understood. This study presents an update of our institution's experience with microsphere brachytherapy in patients with liver metastases from uveal melanoma and has a secondary aim to evaluate whether PETderived functional tumor parameters have predictive value for hepatic progression-free survival (PFS) and overall survival (OS). 17 This report represents the largest reported series of patients treated with 90 Y liver brachytherapy for metastatic uveal melanoma.
METHODS

Patients and 90 Y Microsphere Brachytherapy
After IRB approval, we reviewed the medical records of patients with biopsy-confirmed liver metastases from uveal melanoma that were consecutively treated with 90 Y resin microsphere brachytherapy. 90 Y resin microspheres (SIR-Spheres; SIRTEX Medical, Sydney, Australia) have been approved by the Food and Drug Administration for the treatment of unresectable, metastatic liver tumors from colorectal cancer and were used in an off-label manner. Nine patients were treated on a clinical trial.
A multidisciplinary team selected patients eligible for this treatment including: radiation oncology, interventional radiology, and medical oncology. This treatment was frequently offered as a salvage therapy for progressive disease after immunoembolization or TACE. 10, 14 Eligibility criteria have previously been described and included patients with liverdominant, unresectable disease, and typically with <50% liver tumor burden. 17, 25 Standard exclusion criteria for this procedure have previously been described and were used during patient selection. 17, 25 Patients eligible for this therapy had adequate liver (bilirubin <1.8 mg/dL, albumin >3.0 g/dL, no ascites) and renal function (creatinine r2.0 mg/dL). Patients who had received previous radiation therapy to the liver were excluded; however, retreatment with microspheres was permitted in select cases. Preparatory 3-phase, contrast-enhanced CT, MRI, and PET/CT were performed to assess tumor volume. Pretreatment arteriogram; embolization of nontarget, extrahepatic vessels; and prescription of 90 Y resin microsphere activity using the body surface area method have previously been described. 17 A dose reduction of 25% was applied to patients who had received prior catheter-directed liver therapies. 99m Tc-macroaggregated albumin single-photon emission CT was also performed to determine lung shunt fraction, tumor-to-normal liver uptake ratio, and subsequently calculate nominal dose to the tumor, lung, and liver. Depending on the anatomic distribution of tumor, patients received either whole liver or lobar delivery of microspheres. In addition, whole-liver therapy performed in a staged manner with sequential embolization of individual lobes was permitted and has been described in the literature. 25 
Assessment of Treatment Response
Clinical follow-up included comprehensive history and physical examinations, toxicity evaluation, and laboratory studies 1 month after treatment and then every 3 months that followed. The degree of toxicity was determined with the Common Terminology Criteria for Adverse Events. PET/CT, CT, and MRI were also performed at these time intervals and were assessed by nuclear medicine and radiology specialists. Treatment response with anatomic imaging was assessed using Response Evaluation Criteria in Solid Tumors (RECIST), assessing up to 5 tumor foci. 26 Treatment response was also assessed in up to 5 lesions on PET/CT, where available, because standard criteria may be insensitive when assessing response to interventional treatments, including 90 Y radioembolization. [26] [27] [28] [29] Response assessment criteria of PET/CT continue to evolve in the literature with no current standard. In this study, response assessment criteria for PET/CT were similar to those used in prior studies: patients had a partial response if there was >25% decrease in SUV max at 3 months after treatment, complete response if there was normalization of SUV max , and progressive disease if there was >25% increase in SUV max . 23, 24 
Measurement of Functional Tumor Parameters
After administration of 13-17 mCi of 18 F-FDG, wholebody PET/CT was obtained 75 minutes after injection using a Biograph 6 (Siemens Medical Solutions, Knoxville, TN). A low-dose, coregistered CT was obtained on the same area and emission data were reconstructed with attenuation correction based on the coregistered CT. Commercially available software (MIM Maestro, MIM Software Inc., Cleveland, OH) was used to delineate liver tumors on PET/CT. To reduce observer bias, tumors were automatically contoured using a previously described threshold technique. 24 The SUV threshold was determined individually for each patient and was defined to be the SUV max of normal, uninvolved liver parenchyma plus 2 SDs. The median SUV threshold was 3.3 (range, 2.0 to 4.6). Tumor volumes measuring <2 mL were excluded from the analysis. The results of the autocontouring were verified on the coregistered CT to confirm exclusion of physiological FDG uptake in the nearby kidneys and gastrointestinal tract. MTV, TGA, and SUV max were assessed from the summation of the intrahepatic tumor volumes. Liver tumors were not counted or considered individually due to the large number of patients with innumerable liver metastases or multiple, confluent tumors. MTV defines the volume of tumor on the basis of metabolic activity that is higher than the surrounding normal tissue uptake. SUV max is the portion of the tumor that demonstrates maximum metabolic activity. TGA is the product of the MTV and the mean SUV value in the tumor(s).
Statistical Methods
Survival analyses were conducted by using time from treatment until progression or death. Patients alive or without progression are censored at the date of last clinical follow-up. Survival times were analyzed by Kaplan-Meier method. Logrank test was used for univariate analysis and multivariate analysis was performed on significant univariate predictors using the Cox proportional hazards regression. Measures of MTV were excluded from multivariate testing as they are highly correlated with TGA. Statistical tests were performed at the 5% level of significance.
RESULTS
Patient and Treatment Characteristics
A total of 71 patients were consecutively treated with 90 Y microsphere brachytherapy from May 2007 through December 2012. Patients were followed for a median of 9.9 months (95% confidence interval [CI], 7.8-12.0) after treatment. Patient and treatment characteristics are presented in Table 1 . Sex was well balanced and patients had excellent performance status.
Extrahepatic metastases and monosomy 3 genetic aberrations were common.
The median time from the diagnosis of liver metastases to 90 Y microsphere brachytherapy was 9.8 months (95% CI, 7.4-12.2) and 82% of patients had received prior liver-directed therapies ( Table 1) . Five patients were treated to the whole liver in a single fraction and 14 received unilobar delivery only. The remainder of the patients received fractionated treatment to the whole liver, most commonly through selective, lobar embolization of the left and right hepatic artery in staged, 2 fraction treatment courses (Table 1 ). Seven patients underwent 3 or more radioembolization procedures during the period of follow-up. Such retreatments were performed in the event of disease recurrence or progression (n = 4), due to anatomic considerations (n = 2), and due to arterial dissection resulting in premature termination of a planned delivery with repeat treatment at a later date (n = 1). There was a wide range of delivered activities for lobar and whole-liver treatments, with a median of 36.3 Gy delivered to tumor (Table 1) .
Clinical Response and Patient Survival
There were no treatment-related deaths. Before treatment, 17 patients had preexisting liver dysfunction (grade 1 or 2 elevation of liver function tests) caused by tumor burden or prior liver-directed therapies. Liver function test elevation was observed in 34 patients (48%) after radioembolization, including 5 patients (7%) with grade 2 or 3 toxicity. Nonhepatic toxicities were frequent but self-limiting: grader2 fatigue in 31 (44%), grader2 nausea in 11 (15%), and grader2 abdominal discomfort in 18 (25%). The temporal responses of liver toxicities in patients with uveal melanoma after 90 Y microsphere brachytherapy administered at our institution have previously been reported. 18 Treatment response of target lesions at 3 months after treatment was evaluated with CT or MRI in 61 patients (86%) and was as follows: partial response in 5 (8%), stable in 32 (52%), and progression in 24 (39%). Treatment response on PET/CT at 3 months after treatment was evaluable in 29 patients and was more favorable: partial response in 10 (34%), stable in 14 (48%), and progression in 5 (17%). At the time of analysis, 52 patients had progression in the liver with a median hepatic PFS of 5.9 months (range, 1.3 to 19.1 mo).
Survival data were available for all 71 patients and 56 had died at the time of analysis. Median OS after microsphere brachytherapy was 12.3 months (range, 1.9 to 49.3 mo). Median OS after the diagnosis of the primary ocular tumor and liver metastases was 55.6 months (range, 22 to 226 mo) and 23.9 months (range, 6.2 to 69.0 mo), respectively.
Outcomes were compared among patients receiving brachytherapy as a salvage therapy (n = 58) or as a first-line therapy after diagnosis of liver metastases (n = 13). OS after liver brachytherapy was significantly longer in the nonsalvage group compared with the salvage group (median OS not reached vs. 10.8 mo, P = 0.01). Although this could reflect different sensitivities to therapy among the subgroups, it may also be related to the time interval between diagnosis of liver metastases and brachytherapy, which was longer in the salvage group (11.3 vs. 2.1 mo). Regardless, there was no detectable difference in radiographic response to therapy or hepatic PFS (P = 0.37) among the subgroups. In addition, there was no discernable difference in OS after the diagnosis of liver metastases among the 2 subgroups (P = 0.57).
Metabolic Response and the Predictive Value of PET/CT
Fifty patients (21 men and 29 women) had pretreatment PET/CT and 29 patients (7 men and 22 women) had both pretreatment and posttreatment PET/CT scans available for review. OS in these 50 patients was highly similar to the study cohort (log-rank, P = 0.87) indicating that this is a representative population of patients treated.
Pretreatment PET/CT scans performed at a median of 16 days before microsphere brachytherapy demonstrated a median SUV max of 6.9 (range, 0 to 40.3), median MTV of 57.2 mL (range, 0 to 1570.2 mL), and median TGA of 221.8 mL (range, 0 to 5733.0 mL). Pretreatment MTVs were similar to contoured tumor volume on anatomic imaging (paired t test, P = 0.34). Posttreatment PET/CT performed at a median of 89 days after therapy demonstrated a median SUV max of 5.9 (range, 0 to 12.2), median MTV of 30.1 mL (range, 0 to 1198.3 mL), and median TGA of 157.7 mL (range, 0 to 6527.1 mL). The changes in functional tumor parameters in patients who responded to microsphere brachytherapy were (mean ± SD) SUV max decrease of 1.5 ± 1.8, MTV decrease of 203.7 ± 437.0 mL, and TGA decrease of 527.1 ± 1098.3 mL (Fig. 1) .
Univariate analysis of pretreatment clinical features demonstrated that female sex, MTV, and TGA are significantly correlated with both hepatic PFS and OS after microsphere brachytherapy ( Table 2) . Female sex and TGA retained significance in a multivariate Cox proportional hazards model after adjusting for age, KPS, the presence of extrahepatic disease, and SUV max . MTV was excluded from multivariate analysis as the data are highly correlated with TGA. Patients were stratified by TGA less than or greater than or equal to 225 g, which approximates the median value. Patients with low TGA had a median OS of 17.2 versus 9.7 months observed in those patients with high TGA (HR for death 0.40; 95% CI, 0.20-0.81; P = 0.01) (Fig. 2) .
DISCUSSION
Uveal melanoma is remarkable for its predilection to metastasize to the liver. Despite routine clinical surveillance for early detection of metastatic disease, recent series continue to report unfavorable survival times, thus highlighting the need for liver-targeted therapies. 4, 30, 31 This study describes clinical outcomes for a large series of patients receiving a novel, liverdirected therapy and substantiates preliminary reports proposing that 90 Y microsphere brachytherapy is an effective treatment for liver metastases from uveal melanoma. [19] [20] [21] The rates of response and PFS in our patient population are comparable with previously published studies. 17, [19] [20] [21] In previous observational studies, the median OS of patients with metastatic uveal melanoma ranges from 2 months in those patients receiving no treatment to 12.5 months in unselected patients receiving therapies like surgical resection, palliative external beam radiotherapy, TACE, isolated hepatic perfusion, systemic chemotherapy, or immunotherapy. 4, [9] [10] [11] [12] [13] [14] [15] [16] 30 Furthermore, modern prognostic models for metastatic uveal melanoma estimate median survival to be only 14.9 months in a subset of patients with the most favorable prognostic features. 31 Our observed survival of 23.9 months after the diagnosis of liver metastases compares favorably with these series. This figure also compares favorably to our institution's historic control from a phase I study of liver immunoembolization for uveal melanoma in which median OS was 14.4 months in 34 patients, most of whom had not received prior therapy for liver metastases. 14 Furthermore, the observed median OS of 12.3 months after microsphere brachytherapy is especially encouraging when compared with a second institutional historic control from a phase II trial of liver chemoembolization in which median OS was 5.2 months for all patients and 9.8 months in those patients with limited tumor burden. 10, 32 Although direct comparison between treatment modalities may not be warranted outside the realm of a randomized trial, the survival times reported in the current series are promising.
Although local control was achieved in 60% of patients at 3 months after 90 Y microsphere brachytherapy, rates of measurable, objective response were lower than described in other series. 20 This may be due to inclusion of previously treated patients with considerable tumor burden, or the relative insensitivity of standard RECIST criteria in assessing response to 90 Y microsphere brachytherapy on CT and MRI. In addition, relatively low absorbed doses to the hepatic tumors were delivered in the present series, as a dose reduction was applied in patients who were heavily pretreated with liver-directed therapies. In theory, absorbed dose to the tumor represents an important predictor for treatment response and survival, and there may be a role for dose escalation in future studies.
To date, only a limited number of prognostic factors have been identified to predict poor clinical outcomes in patients with metastatic uveal melanoma. 2, 4, 7, 9, 10, 17, 31 In the current study, we hypothesized that functional tumor parameters are predictive for clinical outcomes after microsphere brachytherapy in patients with liver-dominant disease from metastatic uveal melanoma. Pretreatment TGA has been found to be an independent, negative predictive factor for hepatic PFS and OS, indicating that larger volume and more metabolically active tumors portend for poor outcomes. On univariate analysis, pretreatment MTV was found to be a negative predictive factor for OS and PFS, which is consistent with findings in a separate small series of 7 patients with liver metastases from uveal melanoma. 21 In clinical practice, contoured tumor volume may approximate MTV. Interestingly, SUV max did not demonstrate any predictive value despite its common use in clinical practice. This finding is in agreement with a previously published series and suggests that MTV and TGA are more informative, functional tumor parameters than SUV max , which represents a point measurement. 20 Microsphere liver brachytherapy has significant associated risks of gastrointestinal, liver, and pulmonary toxicity, so patient prognosis should be considered when selecting patients for this complex treatment. Traditionally, physicians have relied on cross-sectional imaging during patient selection for this therapy. Alternative methods to assess liver disease burden and prognosis, such as with PET/CT, could lead to more appropriate utilization microsphere brachytherapy.
Multivariate analysis demonstrated that female sex is an independent predictor of OS and hepatic PFS after microsphere brachytherapy. Similar sex-based findings have been reported in other studies of patients with metastatic uveal melanoma but, until recently, it was not clear whether sex truly carries such strong prognostic weight. 4, 11 Zloto and colleagues recently reviewed a large database of uveal melanoma patients from a national referral center and found that men not only suffered a higher rate of metastases but had an almost 2-fold excess of melanoma-related mortality in the first 10 years after diagnosis. There was no apparent difference in OS among the sexes due to competing risks in female patients. Although the biological reasons for these sex differences are not yet understood, these data have implications for clinical trial planning and testing of new therapies in patients with metastatic uveal melanoma. 33 Our study is limited by the inherent bias in retrospective and nonrandomized analysis. The widespread application of surveillance-imaging for detection of liver metastases in this patient population could also contribute to lead-time bias. Our study is also somewhat limited by the use of a threshold method when defining tumor volume on PET/CT. It is possible that the threshold definition will influence measures of 
